Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C17H21NO · HCl
CAS Number:
Molecular Weight:
291.82
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
atomoxetine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl
InChI
1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1
InChI key
LUCXVPAZUDVVBT-UNTBIKODSA-N
Gene Information
human ... SLC6A2(6530)
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Atomoxetine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
Norepinephrine uptake blocker.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G, et al.
European Neuropsychopharmacology, 19(11), 822-834 (2009)
Irene Joy I Dela Peña et al.
Progress in neuro-psychopharmacology & biological psychiatry, 88, 311-319 (2018-08-21)
Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous neurodevelopmental disorder characterized by varying levels of hyperactivity, inattention, and impulsivity. Patients with ADHD are often classified as (1) predominantly hyperactive-impulsive, (2) predominantly inattentive, and (3) combined type. There is a growing interest in
METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF ATOMOXETINE HYDROCHLORIDE IN BULK AND CAPSULE DOSAGE FORM BY RP-HPLC.
Swathi G, et al.
World Journal of Pharmacy and Pharmaceutical Sciences (2015)
Yue Shen et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 133, 111024-111024 (2020-11-25)
Sudden unexpected death in epilepsy (SUDEP) is the leading cause of mortality in patients with intractable epilepsy. However, the pathogenesis of SUDEP seems to be poorly understood. Our previous findings showed that the incidence of seizure-induced respiratory arrest (S-IRA) was
Dylan Chou et al.
Experimental neurology, 255, 19-29 (2014-03-04)
Fear conditioning in animals has been used extensively to model clinical anxiety disorders. While individual animals exhibit marked differences in their propensity to undergo fear conditioning, the physiologically relevant mediators have not yet been fully characterized. Here, we demonstrate that
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service